Innate Pharma Balance Sheet - Quarterly (OTCMKTS:IPHYF)

Add to My Stocks
$5.41 $0 (0%) IPHYF stock closing price Sep 18, 2018 (Closing)

The financial analysis of a company involves interpreting the income statement, balance sheet and cash flow statements of the company to draw insights like we've done in our Innate Pharma stock analysis. A balance sheet can help evaluate the financial performance of a company. Ratios like return on total assets and current ratio, which also uses cash on hand can be used to measure the operating efficiency of a firm, and can be used to conduct a more accurate Innate Pharma stock analysis. A company releases its balance sheet every quarter along with its quarterly results. Innate Pharma balance sheet as at the end of 2017 Q4 indicates an asset turnover ratio of and debt to equity ratio of . Also check Innate Pharma revenue and Innate Pharma operating cash flow for the same period.

View and download Innate Pharma quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
Fiscal year is Jan - Dec2017 Q42016 Q42016 Q22015 Q4
Cash112.31M194.65M180.56M169.63M
Marketable Securities18.92M24.1M49.78M92.14M
Receivables24.2M35.84M23.65M17.99M
Inventory----
Raw Materials----
Work In Progress----
Finished Goods----
Notes Receivable----
Other Current Assets----
Total Current Assets
155.44M254.6M254.01M279.78M
Property Plant & Equipment----
Accumulated Depreciation----
Net Property Plant & Equipment
12.12M10.06M8.83M6.99M
Investment & Advances----
Other Non-Current Assets----
Deferred Charges----
Intangibles52.21M10.04M11.29M10.79M
Deposits & Other Assets68.47M36.88M44.81M41.94M
Total Assets
288.25M311.59M318.94M339.51M
Notes Payable----
Accounts Payable27.86M22.42M15.38M66.07M
Current Portion Long-Term Debt----
Current Portion Capital Leases----
Accrued Expenses----
Income Taxes Payable----
Other Current Liabilities55.66M62.16M74.12M-
Total Current Liabilities
83.53M84.58M89.5M66.76M
Mortgages----
Deferred Taxes/Income98.34M124.32M144.85M-
Convertible Debt----
Long-Term Debt----
Non-Current Capital Leases----
Other Long-Term Liabilities9.21M7.32M6.41M192.78M
Total Liabilities
191.09M216.23M240.77M259.54M
Minority Interest----
Preferred Stock----
Common Stock Net3.25M2.98M3.04M2.98M
Capital Surplus265.47M207.56M210.65M206.77M
Retained Earnings-117.09M-128.62M-131.29M-121.53M
Treasury Stock----
Other Liabilities-54.48M13.43M-4.23M-8.25M
Shareholders Equity97.15M95.35M78.17M79.97M
Total Liabilities & Shareholders Equity288.25M311.59M318.94M339.51M
All figures in USD. M: Millions of USD, B: Billions of USD.

Most investors just check the Innate Pharma stock price, and Innate Pharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Innate Pharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: Anything that the Innate Pharma company owns and is a part of its books. Assets can be of three types: fixed, current and other assets which includes intangibles, advances. Internet companies typically don't have a lot of assets as there is not much investment in say machinery, equipment etc. Innate Pharma had total assets of $288.25M.
  • Liabilities: This item on the balance sheet implies the firm's, in this case Innate Pharma's, legal obligations including loans, accounts payable, deferred revenue, accrued expenses and mortgages. The total liabilities for IPHYF stock stand at $191.09M.

Innate Pharma Balance Sheet - Key Ratios